The Precision Era of medicine is arriving in Asia Pacific, driven by a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives. Powered by advances in diagnostics, AI and genomic technologies, precision therapies offer curative potential for diseases once deemed untreatable, ushering in a new standard of care across oncology, rare genetic disorders and beyond.
This white paper series explores Asia Pacific’s readiness for the Precision Era — the current transformative period where generically prescribed and regularly administered treatments are increasingly giving way to potentially curative therapies tailored to individuals and their disease.
Drawing on research across more than 1,000 clinical trials across four novel technologies and four markets, we assess the clinical, economic and social benefits of precision therapies, identify systemic barriers to precision therapy adoption, provide recommendations for improvement, and assess the value of widespread adoption across Australia, China, Japan and Korea.
The Precision Era marks a significant turning point for China, as new, innovative therapies drive investment, improve livelihoods and workforce participation, support better patient outcomes, and stronger health systems. But regulation, knowledge and infrastructure must keep up for China to unlock the full potential of this era.
The ‘On the Cusp of a Cure’ white paper series was supported by an advisory committee of 16 pre-eminent regional experts in precision medicine, economic and health policy, and patient experience across Australia, China, Japan and Korea. It was also sponsored by Johnson & Johnson.
Download the PDF to discover how precision therapies can drive life-changing outcomes and sustainable growth.
L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2025 L.E.K. Consulting LLC
07212025100745